Postapproval Changes and Postmarketing Reporting of Adverse Drug Experiences

Approval of an abbreviated new drug application (ANDA) is only the beginning of a generic drug product’s history, as there are numerous postapproval requirements and activities to ensure that marketed drug products remain safe and effective. This chapter discusses a few of the important postapproval requirements from a regulatory affairs perspective.